GFI1 and myeloproliferative disorder: Since it is well known that patients with MPN can develop AML after secondary mutations [58–61], it is conceivable that our mouse models mimic the situation in human AML patients who already carry additional mutations and in combination with low GFI1 expression have a faster disease progression from a previous less malignant MPN.